-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Edited by WuXi AppTec Content Team
In September, the FDA is expected to make approval decisions on the following four drugs, detailed in the table below
▲New drugs that are expected to be approved in the United States in September (drawing by WuXi AppTec’s content team, click to see a larger image)
Company Name: Spectrum Pharmaceuticals
Indications: Chemotherapy-induced neutropenia
Drug name: futibatinib
Company Name: Taiho Oncology
Indications: locally advanced or metastatic cholangiocarcinoma
Taiho Oncology's futibatinib, a selective irreversible oral small molecule inhibitor of FGFR1, 2, 3, and 4, is seeking FDA approval for the treatment of patients with FGFR2 gene rearrangements (including gene fusions) ) in previously treated patients with locally advanced or metastatic cholangiocarcinoma
Learn more about FDA-approved new drugs
Please click the image below or scan the QR code to visit our applet